Adamis Pharmaceuticals Q2 EPS $(3.40) Up From $(4.20) YoY, Sales $6.95K Down From $39.85K YoY
Portfolio Pulse from Benzinga Newsdesk
Adamis Pharmaceuticals reported Q2 losses of $(3.40) per share, a 19.05% increase YoY. Sales were $6.95K, a 82.57% decrease YoY.
August 21, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Adamis Pharmaceuticals reported a YoY increase in losses but a significant decrease in sales.
The company reported increased losses and significantly decreased sales compared to the same period last year. This could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100